pateclizumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458268914

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu/o

| target = lymphotoxin alpha

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1202526-59-7

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = QOK1YYH7J2

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG = D10187

| KEGG_Ref = {{keggcite|changed|kegg}}

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| C = 6436 | H = 9910 | N = 1710 | O = 2004 | S = 44

| synonyms = MLTA3698A

}}

Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url =https://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf }}{{dead link|date=December 2021|bot=medic}}{{cbignore|bot=medic}}[http://www.ama-assn.org/resources/doc/usan/x-pub/pateclizumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab], American Medical Association.{{cite journal |vauthors=Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC |title=Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study) |journal=Arthritis Res. Ther. |volume=16 |issue=5 |pages=467 |date=October 2014 |pmid=25359150 |pmc=4243296 |doi=10.1186/s13075-014-0467-3 |doi-access=free }}{{cite journal |vauthors=Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC |title=Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial |journal=Arthritis Res. Ther. |volume=14 |issue=1 |pages=R6 |date=January 2012 |pmid=22225620 |pmc=3392792 |doi=10.1186/ar3554 |doi-access=free }}{{cite journal |vauthors=Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G |title=Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates |journal=Reprod. Toxicol. |volume=63 |pages=82–95 |date=August 2016 |pmid=27211603 |doi=10.1016/j.reprotox.2016.05.014 |s2cid=41454952 }}{{cite journal |vauthors=Hirose T, Fukuma Y, Takeshita A, Nishida K |title=The role of lymphotoxin-α in rheumatoid arthritis |journal=Inflamm. Res. |volume=67 |issue=6 |pages=495–501 |date=June 2018 |pmid=29541795 |doi=10.1007/s00011-018-1139-6 |s2cid=3910200 }}

This drug was developed by Genentech/Roche.